New Expansion for BalanCD CHO Media Platform Portfolio for Bioprocessing
The BalanCD CHO media portfolio is designed to ensure maximized growth, viability, and productivity of CHO cell lines.
FUJIFILM Irvine Scientific, Inc. announced its growth of the BalanCD Chinese Hamster Ovary (CHO) Media Platform portfolio with the addition of two new, chemically defined growth media- BalanCD CHO Perfusion and BalanCD CHO DG44.
The BalanCD CHO media portfolio is designed to ensure maximized growth, viability, and productivity of CHO cell lines via a scalable platform for reliable production and seamless workflow through all stages of development and manufacture, including small-scale shake flasks to large bioreactors. The new additions increase the platform with specific media designed to support DG44 cell lines and perfusion culture platforms for the commercialization of monoclonal antibodies, recombinant proteins, biosimilars, and other biomolecule-based biotherapeutics.
According to the press release, the BalanCD CHO Perfusion medium is a chemically defined, animal component-free medium optimized to deliver robust cell growth and productivity in steady-state, perfusion CHO culture. This medium is verified to meet industry performance standards for perfusion culture conditions including volumetric productivity (VP), cell specific perfusion rates (CSPR), and vessel volumes per day (VVD).
Additionally, BalanCD CHO Perfusion is a complete, ready-to-use medium that is adaptable and scalable for a variety of perfusion culture platforms, including perfusion mimic and perfusion-capable bioreactors. It is designed for high cell density conditions and to deliver high titers, and BalanCD CHO DG44 medium is specifically created for optimal growth and productivity of CHO DG44 cell lines. It also supports both batch and fed-batch cultures, which makes it highly compatible with a wide range of culture platforms and transfection reagents.
“With CHO cells being such a pivotal part of many biotherapeutic development and manufacture pipelines, FUJIFILM Irvine Scientific designed the BalanCD CHO platform to deliver consistent, high-quality growth of CHO cells and production of biomolecules to accelerate the development and manufacture of life-saving therapies for patients around the world and achieve more cost-efficiencies within biotherapeutic manufacturing,” said Erik Vaessen, chief business officer, FUJIFILM Irvine Scientific, in a press release.
Source: BusinessWire
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
